US biotech Regeneron Pharmaceuticals (Nasdaq: REGN) yesterday announced encouraging initial data from an ongoing Phase I/II/III clinical trial of its antibody cocktail, casirivimab and imdevimab, in hospitalized COVID-19 patients requiring low-flow oxygen.
This is the same drug combination that US President Donald Trump received when he was hospitalized with the virus in October, and it is already distributed by the US government, which took out a contract for 300,000 doses. The UK’s AstraZeneca (LSE: AZN) has also started trialling a long-acting antibody combination known as AZD7442,
The analysis was prospectively designed to focus on patients who had not yet mounted their own immune response to SARS-CoV-2 (ie, did not have antibodies at baseline: seronegative), as prior evidence suggested these patients were at greater risk. The primary clinical objective of this initial analysis was to determine if there was sufficient efficacy in these patients to warrant continuing the trial (ie, futility analysis).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze